Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Primal Mist has released two new perfumes, Formulae Alpha and Formulae Beta, after four years of archaeological study, scientific investigation and fragrance design. The Primal Mist line is produced in extremely small quantities, making them exclusive and rare. The company states that each stage of the creation process is hand-crafted, including bottling. Both perfumes are cured for two years before they are ready for release.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51941-primal-mist-releases-formulae-alpha-beta-fragrances-american-perfumer
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52993-st-jude-childrens-research-hospital-comprehensive-human-cancer-genome-data
Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare professionals better educate patients and caregivers about therapy options related to cardiovascular and peripheral diseases, specifically atrial and ventricular arrhythmias, coronary artery disease, heart failure, heart rhythm disorders and peripheral vascular disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43509-boston-scientific-cardioteach-ipad-app
New research debuted at the American Diabetes Association’s 72nd Annual Scientific Session suggests eating raisins three times a day may significantly lower postprandial (post-meal) glucose levels when compared to common alternative snacks of equal caloric value. The study was conducted at the Louisville Metabolic and Atherosclerosis Center (L-MARC) by lead researcher, Harold Bays, MD, medical director and president of L-MARC.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56845-california-raisin-marketing-board-raisins-reduce-post-meal-blood-sugar
Through thousands of hours meeting with women from Dallas to Taipei, Sao Paulo to Paris, Neutrogena® uncovered a universal truth – women are stepping back to examine what’s possible in their lives so they can pursue their dreams. Always on a mission to create, innovate, and rethink what’s possible in skincare, Neutrogena® identified this shared value and was inspired to launch its first-ever global campaign: “Neutrogena. See What’s Possible.™”
“Neutrogena® started as a dream, and through scientific discovery, creative thinking and the resilience to defy expectations without any compromises, a brand was born,” said Alicia Sontag, President, Beauty Care, Johnson & Johnson Consumer Inc. “We support women around the world and are proud to help them put their best face forward as they pursue their own dreams – big or small.”
The “Neutrogena. See What’s Possible™” campaign will debut with a commercial voiced by Brand Ambassador and creative consultant Kerry Washington which features real women following their passions. The empowering video brings to life the brand’s point of view on beauty – what really makes a woman beautiful is the ability to look in the mirror and know that anything is possible. In addition, educational and inspiring digital content designed to encourage her along her journey will be leveraged through social platforms in over 27 countries around the world, making this the largest digitally-driven campaign the brand has ever executed.
To view the multimedia release go to:
http://www.multivu.com/players/English/7770451-neutrogena-see-what-s-possible/
SimplexCalc is a multivariable desktop calculator for Windows. It is small and simple to use but with much power and versatility underneath. It can be used as an enhanced elementary, scientific, financial or expression calculator.
In addition to arithmetic operation, more than hundred built-in constants and functions can also be used in your expression.
SimplexCalc also has the unlimited ability to extend itself by using custom (user-defined) variables. You can add your own variables for SimplexCalc in order to tackle complex problems with ease and fun. Even you can compile formula once and then calculate the result many times with different variable values.
With the brilliant designs and powerful features of SimplexCalc, you can bring spectacular results to your calculating routines.
MultiplexCalc is a multipurpose and comprehensive desktop calculator for Windows. It is small and simple to use but with much power and versatility underneath. It can be used as an enhanced elementary, scientific, financial or expression calculator. MultiplexCalc contains more than hundred internal constants and functions (algebraic, trigonometric, hyperbolic, transcendental, etc;) to satisfy your needs to solve problems ranging from simple elementary algebra to complex equations. Its underling implementation encompasses high precision, sturdiness and multi-functionality.
MultiplexCalc also has the unlimited ability to extend itself by using user-defined variables. You can add your own variables to MultiplexCalc in order to convenience your work. Any instance of a formula can be parsed once, and calculated many times with different variable values.
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced Accelrys Insight and Accelrys Insight for Excel, completing the roll-out of Accelrys’ next-generation cheminformatics suite and providing an interactive, collaborative environment for rapid and effective decision-making in drug discovery. Accelrys Insight and Accelrys Insight for Excel offer research scientists an entirely new way of accessing, visualizing and analyzing data that is locked in disparate locations across internal discovery teams and networked external partners, helping to lower long-standing barriers to bringing innovative therapeutics to market faster and more cost effectively.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62191-accelrys-insight-next-generation-decision-making-in-scientific-discovery
